Predicting responses in metastatic lung cancer using AI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to develop a predictive response algorithm for patients with metastatic non-small cell lung cancer (NSCLC) by utilizing an artificial intelligence platform. It will gather comprehensive patient data from clinical, laboratory, radiological, and pathological sources to analyze correlations and connections over time. The focus is on identifying non-responders to immunotherapy and chemo-immunotherapy, with two specific cohorts being studied. The goal is to create a reliable predictive score that evolves with incoming data, enhancing treatment personalization.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Patients with histological or cytological diagnosis of NSCLC
* Stage IV according to investigator's staging procedures (or any locally advanced tumour not feasible for local radical treatment)
* Treatment with at least 1 cycle of mono-immunotherapy or chemo-immunotherapy (as per clinical practice)
* Availability of follow-up

Exclusion criteria:

* Patients with other thoracic tumours non-NSCLC (i.e. SCLC)
* Stage other than IV or feasible for radical treatment upfront
* Treatment within clinical trials (with combination regimens different from the aforementioned combinations)
* Lost to follow-up

Where it's running

• Francesca Rita Ogliari
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Francesca Rita Ogliari, MD
• Email: oncologia.medica@hsr.it
• Phone: 0039 02 2643 2643

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sacituzumab tirumotecan plus furmonertinib for advanced EGFR‑mutant non‑squamous lung cancer after EGFR‑TKI and platinum chemotherapy

  This Phase II trial will test whether combining sacituzumab tirumotecan with furmonertinib helps people with advanced EGFR‑mutant non‑squamous NSCLC who progressed after EGFR‑TKI and platinum chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07548060

• Real-world first-line atezolizumab for stage IV NSCLC with PD-L1 ≥50% in Türkiye

  This project will see how well first-line atezolizumab works and how safe it is for adults with stage IV non-small cell lung cancer whose tumors have PD-L1 ≥50% and no targetable mutations in routine care in Türkiye.

  Recruiting at 15 sites Antalya Training and Research Hospital · Adana and 24 other locations · NCT07279402

• Combination treatment for advanced lung cancer

  This study is testing a new combination treatment for advanced lung cancer to see if it works better than the standard single drug treatment.

  Recruiting at 47 sites Phase 3 ImmunityBio, Inc. · Hot Springs, Arkansas and 48 other locations · NCT06745908

• Testing Repotrectinib in Elderly and Frail Patients with Advanced NSCLC

  This study is testing a new cancer drug called repotrectinib to see if it helps older and frail patients with advanced lung cancer feel better and tolerate the treatment well.

  Recruiting at 20 sites Phase 2 Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Aix-en-Provence, Bouches Du Rhône and 19 other locations · NCT06552234

• Using Stereotactic Body Radiotherapy for treating metastatic lung cancer with limited progression

  This study is testing if adding a special type of radiation therapy to standard treatment can help people with advanced lung cancer live longer and feel better after their first round of chemotherapy.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06523673

• Combining hormone therapy and immunotherapy for advanced lung cancer

  This study is testing if combining hormone therapy with a type of immunotherapy can help older men with advanced lung cancer respond better to treatment.

  Recruiting Jinzhou Medical University · Zhengzhou, Henan · NCT06512207

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.